Skip to main content

Erwinia asparaginase (crisantaspase) increases plasma levels of serine and glycine

Journal articles
Bollino, D; Claiborne, JP; Hameed, K; Ma, X; Tighe, KM; Carter-Cooper, B; Lapidus, RG; Strovel, ET; Emadi, A
Published in: Frontiers in Oncology
December 12, 2022

The impact of asparaginases on plasma asparagine and glutamine is well established. However, the effect of asparaginases, particularly those derived from (also called crisantaspase), on circulating levels of other amino acids is unknown. We examined comprehensive plasma amino acid panel measurements in healthy immunodeficient/immunocompetent mice as well as in preclinical mouse models of acute myeloid leukemia (AML) and pancreatic ductal adenocarcinoma (PDAC) using long-acting crisantaspase, and in an AML clinical study (NCT02283190) using short-acting crisantaspase. In addition to the expected decrease of plasma glutamine and asparagine, we observed a significant increase in plasma serine and glycine post-crisantaspase. In PDAC tumors, crisantaspase treatment significantly increased expression of serine biosynthesis enzymes. We then systematically reviewed clinical studies using asparaginase products to determine the extent of plasma amino acid reporting and found that only plasma levels of glutamine/glutamate and asparagine/aspartate were reported, without measuring other amino acid changes post-asparaginase. To the best of our knowledge, we are the first to report comprehensive plasma amino acid changes in mice and humans treated with asparaginase. As dysregulated serine metabolism has been implicated in tumor development, our findings offer insights into how leukemia/cancer cells may potentially overcome glutamine/asparagine restriction, which can be used to design future synergistic therapeutic approaches.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Frontiers in Oncology

DOI

EISSN

2234-943X

Publication Date

December 12, 2022

Volume

12

Publisher

Frontiers Media SA

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bollino, D., Claiborne, J. P., Hameed, K., Ma, X., Tighe, K. M., Carter-Cooper, B., … Emadi, A. (2022). Erwinia asparaginase (crisantaspase) increases plasma levels of serine and glycine. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1035537
Bollino, Dominique, J Preston Claiborne, Kanwal Hameed, Xinrong Ma, Kayla M. Tighe, Brandon Carter-Cooper, Rena G. Lapidus, Erin T. Strovel, and Ashkan Emadi. “Erwinia asparaginase (crisantaspase) increases plasma levels of serine and glycine.” Frontiers in Oncology 12 (December 12, 2022). https://doi.org/10.3389/fonc.2022.1035537.
Bollino D, Claiborne JP, Hameed K, Ma X, Tighe KM, Carter-Cooper B, et al. Erwinia asparaginase (crisantaspase) increases plasma levels of serine and glycine. Frontiers in Oncology. 2022 Dec 12;12.
Bollino, Dominique, et al. “Erwinia asparaginase (crisantaspase) increases plasma levels of serine and glycine.” Frontiers in Oncology, vol. 12, Frontiers Media SA, Dec. 2022. Crossref, doi:10.3389/fonc.2022.1035537.
Bollino D, Claiborne JP, Hameed K, Ma X, Tighe KM, Carter-Cooper B, Lapidus RG, Strovel ET, Emadi A. Erwinia asparaginase (crisantaspase) increases plasma levels of serine and glycine. Frontiers in Oncology. Frontiers Media SA; 2022 Dec 12;12.

Published In

Frontiers in Oncology

DOI

EISSN

2234-943X

Publication Date

December 12, 2022

Volume

12

Publisher

Frontiers Media SA

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3202 Clinical sciences